A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Standard of Care (SOC) in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma (SUNNIFORECAST)

Nivolumab (Opdivo®), Ipilimumab (Yervoy®)

Status: Studie beendet

Klinische Settings

Beteiligte

Identifier

Links

Kontakt